Payers typically use tools such as prior authorization and utilization review to manage cystic fibrosis treatments. But they are on the cusp of implementing more innovative strategies that might help to improve adherence while addressing the cost of cystic fibrosis drugs, which typically receive orphan-drug status, PBM experts say.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.